Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention

The elevated methionine (MET) use by cancer cells is termed MET dependence and may be the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo. We previously reported that rMETase, administrated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Kawaguchi, Kei, Han, Qinghong, Li, Shukuan, Tan, Yuying, Igarashi, Kentaro, Kiyuna, Tasuku, Miyake, Kentaro, Miyake, Masuyo, Chmielowski, Bartosz, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Singh, Arun S., Eckardt, Mark A., Unno, Michiaki, Eilber, Fritz C., Hoffman, Robert M.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5914727/
https://ncbi.nlm.nih.gov/pubmed/29187018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1405195
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados